All In MedTech

FDA Clearance Tracker · P150031

VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM

Premarket approval (PMA) is the pathway for the highest-risk devices. FDA reviews clinical evidence of safety and effectiveness before approving.

Last checked: Nov 20, 2026Latest source record: Dec 8, 2017 (this decision)Source: openFDAMethods & limitations

PMA

Decided

Dec 8, 2017

Approved

Time to decision

835 days

Received Aug 26, 2015. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA

Device class

Class III

The decision

FDA number
P150031
Device name
VERCISE DEEP BRAIN STIMULATION (DBS)SYSTEM
Applicant location
Valencia, CA
Received
Aug 26, 2015
Decided
Dec 8, 2017
Decision
Approved
Supplements
95 in FDA's data for this PMA. See them on the FDA record

Device type

Device class
Class III

Every decision under product code NHL

FDA's approval statement

As written in FDA's record.

Approval for the Vercise DBS System. The device is indicated for use in bilateral stimulation of the subthalamic nucleus (STN) in the treatment of patients with moderate to advanced levodopa-responsive Parkinsons disease (PD), which is not adequately controlled with medication.

How new is this?

These are facts about FDA's records. They are not a judgment about the device.

  • It is not the first decision under product code NHL. The earliest in FDA's data is P960009-S007, decided Jan 14, 2002.
  • It is not on FDA's public list of Breakthrough Devices with marketing authorization (list dated June 30, 2026). FDA does not publish which devices hold the designation before they are authorized, and the list is updated only a few times a year.

Source documents

Other decisions for Boston Scientific Corp

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.